Led by Dr. Mao Mao and a multidisciplinary team from leading Chinese hospitals, the multicenter retrospective study enrolled 1,814 participants, including 1,095 lung cancer patients. Blood samples ...
SAN ANTONIO--(BUSINESS WIRE)-- bioAffinity Technologies, Inc. (Nasdaq: BIAF; BIAFW), a biotechnology company focused on noninvasive diagnostics and early cancer detection, today announced a ...
bioAffinity Technologies, Inc. (Nasdaq: BIAF; BIAFW),a biotechnology company advancing noninvasive diagnostics for lung cancer and other lung diseases, today announced continued sales growth of its ...